Authors' response: Proliferative retinopathy in chronic myeloid leukemia and diabetes: A "double whammy"

Usman Naeem; Ameen Alkhateeb; Abdulqadir J Nashwan; Mohamed A Yassin

doi:10.1016/j.survophthal.2022.07.004

Authors' response: Proliferative retinopathy in chronic myeloid leukemia and diabetes: A "double whammy"

Surv Ophthalmol. 2022 Nov-Dec;67(6):1731-1732. doi: 10.1016/j.survophthal.2022.07.004. Epub 2022 Jul 21.

Authors

Usman Naeem¹, Ameen Alkhateeb¹, Abdulqadir J Nashwan², Mohamed A Yassin³

Affiliations

¹ Ophthalmology Department, Hamad Medical Corporation (HMC), Doha, Qatar.
² Hematology Section, Medical Oncology Department, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar. Electronic address: nursing861@gmail.com.
³ Hematology Section, Medical Oncology Department, National Center for Cancer Care and Research, Hamad Medical Corporation (HMC), Doha, Qatar.

PMID: 35872011
DOI: 10.1016/j.survophthal.2022.07.004

Abstract

This editorial discusses that the diabetic proliferative retinopathy progresses as a result of ischemia angiogenic stimuli, which may be exacerbated by concomitant CML retinopathy generating increased blood viscosity and vascular endothelial growth factor levels.

Keywords: Chronic myeloid leukemia; diabetes; ophthalmic manifestations; proliferative retinopathy.

Publication types

Letter
Comment

MeSH terms

Diabetes Mellitus*
Diabetic Retinopathy* / complications
Diabetic Retinopathy* / epidemiology
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / complications
Vascular Endothelial Growth Factor A / metabolism
Vascular Endothelial Growth Factors

Substances

Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors